Synthesis and evaluation of aryliden- and hetarylidenfuranone derivatives of usnic acid as highly potent Tdp1 inhibitors |
| |
Authors: | Olga Zakharova Olga Luzina Alexandra Zakharenko Dmitry Sokolov Alexandr Filimonov Nadezhda Dyrkheeva Arina Chepanova Ekaterina Ilina Anna Ilyina Kristina Klabenkova Boris Chelobanov Dmitry Stetsenko Ayesha Zafar Chatchakorn Eurtivong Jóhannes Reynisson Konstantin Volcho Nariman Salakhutdinov Olga Lavrik |
| |
Affiliation: | 1. Novosibirsk Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russian Federation;2. N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russian Federation;3. Novosibirsk State University, Novosibirsk 630090, Russian Federation;4. School of Chemical Sciences, University of Auckland, New Zealand |
| |
Abstract: | Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a repair enzyme for stalled DNA-topoisomerase 1 (Top 1) cleavage complexes and other 3′-end DNA lesions. Tdp1 is a promising target for anticancer therapy, since it can repair DNA lesions caused by Top1 inhibitors leading to drug resistance. Hence, Tdp1 inhibition should result in synergistic effect with Top1 inhibitors. Twenty nine derivatives of (+)-usnic acid were tested for in vitro Tdp1 inhibitory activity using a fluorescent-based assay. Excellent activity was obtained, with derivative 6m demonstrating the lowest IC50 value of 25?nM. The established efficacy was verified using a gel-based assay, which gave close results to that of the fluorescent assay. In addition, molecular modeling in the Tdp1 substrate binding pocket suggested plausible binding modes for the active analogues. The synergistic effect of the Tdp1 inhibitors with topotecan, a Top1 poison in clinical use, was tested in two human cell lines, A-549 and HEK-293. Compounds 6k and 6x gave very promising results. In particular, 6x has a low cytotoxicity and an IC50 value of 63?nM, making it a valuable lead compound for the development of potent Tdp1 inhibitors for clinical use. |
| |
Keywords: | Corresponding author at: Novosibirsk Institute of Chemical Biology and Fundamental Medicine Siberian Branch of the Russian Academy of Sciences Novosibirsk 630090 Russian Federation. |
本文献已被 ScienceDirect 等数据库收录! |
|